














190The Pretransplantation Serum Cytokine Profile
in Allogeneic Stem Cell Recipients Differs from Healthy
Individuals, and Various Profiles are Associated with
Different Risks of Posttransplantation Complications
Hakon Reikvam,1,2 Knut Anders Mosevoll,2 Guro Kristin Melve,3 Clara-Cecilie G€unther,4
Malvin Sjo,2 Pal-Tore Bentsen,2 Øystein Bruserud1,2Cytokines play a key role in regulation of normal and malignant hematopoiesis, angiogenesis, and
inflammation. Serum levels of several cytokines are altered in patients with hematologic malignancies, and
pretransplant cytokine levels seem to have a prognostic impact in patients treated with allogeneic stem
cell transplantation. However, the cytokine system constitutes an interacting functional network, and it
may therefore be more relevant to look at serum cytokine profiles rather than the serum levels of single
cytokines in allotransplanted patients. We therefore investigated the pretransplantation serum levels of
35 cytokines in a group of 44 consecutive allogeneic stem cell transplantation patients, mainly with a primary
diagnosis of acute leukemia. Serum samples were collected before the start of myeloablative conditioning
therapy when all patients were in complete hematologic remission. Unsupervised hierarchical clustering anal-
ysis identified threemajor patient groups/subsets. These groups differed especially in the levels of hepatocyte
growth factor and granulocyte-colony stimulating factor, and one of the groups was characterized by low
early treatment-related morbidity and high levels of hepatocyte growth factor and granulocyte-colony stim-
ulating factor. The degree of weight gain/fluid retention after conditioning therapy did not differ between the
patient subsets, but fluid retention showed a significant correlation with pretransplantation serum levels of
basic fibroblast growth factor. We conclude that the pretransplantation serum cytokine profile shows a con-
siderable variation even between patients in complete hematologic remission and is associated with clinico-
pathologic features.
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The increased antileukemic effect of allogeneic
hematopoietic stem cell transplantation (allo-SCT) is
because of the intensive conditioning therapy and
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6/j.bbmt.2011.10.007these beneficial effects are counteracted by the risk of
severe posttransplantation complications including
serious infections, graft-versus-host disease (GVHD),
and treatment-related organ toxicity [2]. The decision
to recommend allo-SCT therefore has to be individual-
ized based on (1) the expected long-term disease-free
survival with conventional chemotherapy, (2) comor-
bidity, and (3) the risk of serious transplantation-
related complications [3]. There is still a significant
risk of relapse as well as nonrelapse mortality even for
those patients considered to be low risk [3], and im-
proved pretransplantation risk evaluation of individual
patients will be important to improve treatment results.
Cytokines are important regulators of normal and
leukemic hematopoiesis, angiogenesis, and inflamma-
tion/immunity [4,5]. Thus, cytokines are important in
allotransplanted patients both with regard to relapse
risk, hematopoietic, and immune reconstitution as well
as development of posttransplantation complications.
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regulators of hematopoiesis, inflammation, and cancer-
associated angiogenesis [4,6], but several other
cytokines are also important both for leukemogenesis
and chemosensitivity [7-9]. The importance of the
cytokine network in allo-SCT was clearly illustrated by
a recent study describing that high pretransplantation
levels of angioregulatory angiopoietin-2 (Ang-2)were as-
sociated with an adverse prognosis [10]. However, the
cytokine system constitutes an interacting functional
network [11,12], and it may therefore be more relevant
to examine serum cytokine profiles rather single
cytokines, and such profiles seem to have both
a diagnostic value and a prognostic impact for patients
with myeloid malignancies [11,13]. In this context, we
investigated pre- and posttransplantation serum
cytokine profiles for an unselected group of consecutive
allo-SCT patients.MATERIAL AND METHODS
Patient Characteristics
The study was approved by the local Ethics Com-
mittee (Regional Ethics Committee III, University of
Bergen, Norway), and samples were collected after
written informed consent. The study included 44 con-
secutively allotransplanted patients (32 men, 12
women; median age, 47 years; range, 18-61 years) dur-
ing a 53-month period (storage of serum samples be-
fore analysis ranged from 4 to 51 months). These
patients represent all adult patients from a defined geo-
graphic area (Norwegian Health Regions III, IV, and
V) with an available family donor and for whom allo-
SCT was indicated according to the guidelines given
by the official Norwegian Advisory Board for Alloge-
neic StemCell Transplantation. The decision to trans-
plant was made by this committee for all individual
patients. Thus, our study should be regarded as a pop-
ulation-based study.
All except one patient (an Arabic male patient)
were Caucasians. The patients were diagnosed with
de novo acute myeloid leukemia (AML) (20 patients),
myelodysplastic syndrome (MDS)/AML-MDS (seven
patients), B cell acute lymphoblastic leukemia (B-
ALL, nine patients), T cell ALL (T-ALL, four pa-
tients) and chronic myeloid leukemia in blast phase,
chronic myelomonocytic leukemia, aplastic anemia,
and myelofibrosis (one patient each). Serum samples
were collected before start of conditioning therapy
(median, 23 days; range, 3-77 days), and all leuke-
mia/MDS patients were then considered to be in com-
plete hematologic remission.
The patients received myeloablative conditioning
therapy with either busulfan plus cyclophosphamide
(42 patients), antithymocyte globulin plus cyclophos-
phamide, or carmustine, etoposide, cytarabine, andmelphalan. All patients received GVHD prophylaxis
with cyclosporine A plus methotrexate and underwent
transplantation with granulocyte colony-stimulating
factor (G-CSF) mobilized peripheral blood stem cells
derived from HLA-matched family donors. GVHD
was diagnosed according to generally accepted criteria
[14]. Neutrophil reconstitution was defined as 3 con-
secutive days with neutrophil counts of at least 0.2/
0.5  109/L, and platelet reconstitution as platelet
counts exceeding 20/50  109/L for at least 3 consec-
utive days. Capillary leak syndrome was defined as at
least 10% weight gain during 24 hours despite diuretic
therapy.Healthy Controls
The controls included 20 healthy Caucasians with
a median age 42 years (range, 23-57 years; 11 females,
nine males).Analysis of Cytokine Levels
Preparation of serum samples
All venous blood samples were collected into ster-
ile plastic tubes (BD Vacutainer SST Serum Sepa-
ration Tubes, Becton-Dickenson; Franklin Lakes, NJ)
and allowed to coagulate for 120 minutes at room tem-
perature (18C) before centrifugation (300  g for 10
minutes) and serum collection. All samples were im-
mediately frozen at 270C until analyzed. Repeated
freezing and thawing were avoided. The average stor-
age time for patients was 27 months and for the con-
trols, 25 months.
Analysis of serum samples
Serum samples were stored at 280C until ana-
lyzed. Cytokine level were determined by Luminex
analyses (R&D Systems, Abingdon, UK) and included
(1) the immunomodulatory interferon-g (IFN-g),
CD40 ligand (CD40L), tumor necrosis factor-a
(TNF-a); (2) the interleukins IL-1a, IL1-b, IL-1RA,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-10,
IL-12, IL-13, IL-17, and IL-22; (3) the chemokines
CCL3, CCL4, CCL5, CCL11, CXCL5, CXCL10,
CXCL11; and (4) the growth factors, Ang-1, Ang-2,
G-CSF, granulocyte macrophage colony-stimulating
factor (GM-CSF), vascular endothelial growth factor
(VEGF), thrombopoietin (Tpo), epithelial growth
factor (EGF), hepatocyte growth factor (HGF), and
Leptin. Additional analyses were performed by
enzyme-linked immunosorbent assay (ELISA) (R&D
Systems) and included basic fibroblast growth factor
(bFGF) (high sensitivity), CXCL9, angiogenin,
soluble IL-2a receptor and soluble TNF receptor 1
(TNFR1). The analyses there were performed in du-
plicates strictly according to the manufacturer’s in-
structions. All patients and controls were analyzed in
Table 1. Pretransplantation Serum Cytokine Levels in Allotransplanted Patients: A Comparison with Healthy Controls
Cytokine Patients Healthy Controls P Value
Immunomodulatory cytokines
IFN-g Y 0.86 (0.05-12.02) 7.8 (2.9-11.7) <.0001*
CD40L [ 4639 (220-951904) 1425 (104-10779) .0039
TNF-a Y 1.0 (1.0-41.1) 4.5 (2.3-13.4) <.0001*
Interleukins
IL-1a - 1.0 (1.0-41.1) 1.0 (1.0-1.0) n.s
IL-1b - 0.2 (0.2-7.9) 0.5 (0.2-1.5) n.s
IL-1RA [ 1131 (294-8890) 590 (261-4230) .0051
IL-2 Y 0.5 (0.5-44.7) 7.2 (0.5-13.8) <.0001*
IL-4 Y 2.0 (2.0-35.7) 11.8 (5.0-17.5) <.0001*
IL-6 [ 0.1 (0.1-0.1) 0.3 (0.1-13.9) <.0001*
IL-10 - 1.0 (1.0-12.8) 1.0 (1.0-1.0) n.s
IL-17 [ 1.9 (1.9-57.1) 3.0 (2.0-5.8) .0002*
Chemokines
CCL2 - 211.4 (79.0-581.5) 199 (33-376) n.s
CCL3 Y 15.0 (15.0-178.4) 225.5 (89.0-303.0) <.0001*
CCL4 - 50.2 (17.4-109.5) 52.5 (23.0-110.0) n.s
CCL11 [ 134.1 (37.4-456.5) 81.0 (25.0-263.0) .0010
CXCL5 Y 560 (16-5868) 1284 (341-5307) .0022
CXCL8/IL-8 [ 18.8 (0.1-224.7) 10.7 (2.2-22.8) .0125
CXCL10 - 16.7 (9.0-189.1) 15.3 (6.9-58.4) n.s
CXCL11 [ 80.2 (26.6-434.2) 27.1 (3.6-100.9) <.0001*
Growth factors
TPO - 753 (153-3432) 566 (198-1025) n.s
EGF - 1.0 (1.0-135.0) 26.9 (1.0-378.9) n.s
VEGF - 63.8 (1.1-543.6) 47.9 (16.8-234.5) n.s
HGF - 194 (10-1398) 262 (117-729) n.s
Leptin - 6618 (364-47369) 10670 (1024-61683) n.s
G-CSF [ 9.0 (1.0-81.8) 1.0 (1.0-63.2) .0003*
GM-CSF [ 2.18 (1.17-12.32) 0.9 (0.9-3.6) <.0001*
The table shows the serum levels for 44 patients receiving allo-SCTand 20 healthy controls. The results are presented from left to right as the cytokine
analyzed, the alteration in patients ([ increased, Y decreased), the patient’s levels (median and range), levels in healthy controls (median and range), and
the P value for those cytokines showing statistically significant differences between the two groups (P < .05, Mann-Whitney U test). P values that were
statistically significant also after Bonferroni correction are marked with *. All cytokine concentrations are presented as pg/mL, for cytokine levels not
detected, the values were set to the lowest detectable level in the statistical analyses.
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analyzed with the ELISAs.
Statistical and Bioinformatical Analyses
Bioinformatical analyses were performed using the
J-Express (MolMineAS, Bergen,Norway) [15]. For hi-
erarchical clustering, all values were median normal-
ized standardized and log(2) transformed. The
complete linkage was used as linkage method, and for
distance measured the Pearson correlation was used.
Linear discriminant analysis was performed using the
Ida function from theMASSpackage in theR statistical
software (R Development Core Team. R: A Language
and Environment for Statistical Computing. R Foun-
dation for Statistical Computing, Vienna, Austria,
2011, ISBN 3-900051-07-0 http://www.R-project.
org). Additional statistical analyses were performed
using the Statistical Package for the Social Sciences
version 15.0 (SPSS Inc., Chicago, IL) and GraphPad
Prism 4 (Graph Pad Software, Inc., San Diego, CA).
Pearson correlation for bivariate samples was used for
correlation analyses, and the Mann-Whitney U-test
and the chi-square test were used to compare different
groups. Unless otherwise stated, P values\.05 were
regarded as statistically significant.RESULTS
The Pretransplantation Serum Cytokine Profile
of Acute Leukemia Patients in Complete
Hematologic Remission Differs from Healthy
Controls
We first compared the levels of single cytokines
between all patients and healthy controls, and these re-
sults are summarized in Table 1. The cytokines were
classified according to their main function in acute leu-
kemia patients: (1) immunomodulatory cytokines, (2)
interleukins, (3) chemokines, and (4) growth factors.
The interleukin levels were generally low both for pa-
tients and controls, and even when statistically signifi-
cant differences were observed, the absolute values of
these differences were relatively small. Second, serum
chemokine levels were generally higher, and the statis-
tically significant differences showed larger absolute
values. Finally, immunomodulatory cytokines also
showed statistically significant differences between
the two groups, whereas among the growth factors,
only the increased G-CSF and GM-CSF levels in the
patients reached statistical significance. All these dif-
ferences reached significance also when only the 42
leukemia patients were analyzed, and there were no
Figure 1. Unsupervised hierarchical cluster analyses for 33 different soluble mediators in 44 allo-SCT patients. The serum cytokine profile was de-
termined for 44 consecutive allo-SCT patients, and the concentrations were mean normalized and log(2) converted before Pearson’s correlation
test with complete linkage was used to make a heat map with additional unsupervised hierarchical clustering analyses. Red or green colors indicate
high or low serum concentrations, respectively, relative to the median level in the patient group for each individual cytokine. (Left) The clustering of
each individual cytokine is given at the top of the figure. The left denogram demonstrated that identify two major patient clusters, and each main cluster
could be divided into two subclusters. The upper main cluster is referred to as patient group 1 (16 upper patients), and the two subclusters of the lower
main cluster are referred to as patient groups 2 (16 middle patients) and 3 (12 lower patients), respectively. (Middle) The variation between patients is
illustrated; the red indicates a strong correlation. (Right) The part presents the clinical characteristics of each individual patient (diagnosis, aGVHD grade
2-4, multiorgan failure, early relapse, and weight increase).
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tients. Thus, acute leukemia patients achieving com-
plete remission after intensive chemotherapy show
a significant alteration in their systemic cytokine
profile compared with healthy controls.
To investigate whether the storage time had any
effect on measured cytokine levels, we compared the
levels for patients with .40 months and\12 months
storage time; neither the overall profile nor the levels
of individual cytokines differed between these patients
(data not shown).The Platelet Count Does Not Have Any Major
Impact on the Pretransplantation Serum
Cytokine Profile
Certain cytokines (VEGF, CCL5, CD40L) can be
released at relatively high levels by platelets [16], and
to investigate whether platelet release during ex vivo
sample preparation contributed to these serum levels,
we performed correlation analyses between peripheral
blood platelet counts and these cytokine levels. A weak
correlation was only observed for VEGF (r 5 .3627;
nominal P 5 .0214, Bonferroni P 5 .5778, Pearson’s
correlation), whereas no statistically significant corre-
lations were detected for the other cytokines. Thus,
ex vivo platelet release during handling of samplesdoes not have any major impact on the serum cytokine
profile in our patients.
Unsupervised Hierarchical Clustering Based on
Pretransplantation Cytokine Levels Alone
Identifies a Patient Subset with LowRisk of Early
Posttransplantation Complications
Previous studies have shown that cytokines can be
released in clusters, and this coordinated release may
then reflect common regulatory mechanisms, for ex-
ample, at the transcriptional level [11,12]. We
therefore performed an additional analysis where the
cytokine levels in patients were median normalized
and log(2) transformed before further bioinformatical
analyses were performed (Figure 1). The three
cytokines IL-1b, IL-4, and IL-5 were left out from
this analysis because detectable levels were seen only
for one patient each. Four cytokine clusters were iden-
tified among the remaining 33 soluble mediators
(Figure 1, top), and each of these clusters included
cytokines from various classes (immunomodulatory/
chemokines/interleukins/growth factors):
 Cluster I (left): This cluster included 12 cytokines
that generally showed only minor variations be-
tween most of the patients except for Ang-1,
CXCL5, and EGF. The cluster in addition included
Figure 2. Principal component analysis of the serum cytokine profile for 44 allo-SCT patients. We performed a principal component analysis based on
the serum cytokine profiles and the three patient groups identified in the unsupervised hierarchical cluster analysis (Figure 1, left). Group 1 (Figure 1,
upper 16 patients) and group 2 patients (Figure 1, middle 16 patients) aremarked by different dark symbols, and group 3 (Figure 1, lower 12 patients) with
open symbols. The differences between groups 1 and 2 versus group 3 could also be demonstrated in this alternative analysis, but there was an overlap
between them. The two first principal components could explain 44.8% of the total variance in the data set.
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(IL-7, IL-10, IL-22), the three chemokines CCL4,
CCL11, and CXCL8, and the growth factors
bFGF and VEGF.
 Cluster II (middle left): This cluster included
TNF-a, GM-CSF, IL-6, IL1-RA, and CXCL11.
 Cluster III (middle right): These 10 cytokines
included the immunoregulatory IFN-g, three inter-
leukins (IL-1a, IL-2, IL-17), two chemokines
(CCL2, CCL3), and several growth factors (Ang-
2, G-CSF,
Leptin, Tpo).
 Cluster IV (right): This last cluster included two an-
gioregulatory chemokines (CXCL9, CXCL10) and
two angioregulatory growth factors (HGF, angio-
genin) [7]. The two last members of this cluster
were the two soluble receptors IL-2a receptor and
TNFR1; both these mediators showed relatively
small variation between the patients.
Based on this analysis, we identified two major
patient clusters including the upper 16 and the lower
28 patients, respectively (Figure 1, left); the variation
between patients is also illustrated by the heat map in
the middle part of the figure. Each major cluster could
be divided into two subclusters, and three different
patient groups could then be identified from these
four subclusters (from top to bottom): group 1 com-
prised the 16 patients forming the main cluster 1, and
groups 2 and 3 correspond to the upper respiratory
lower subcluster of the main cluster 2. These three
patient groups did not differ with regard to primary di-
agnosis, development of capillary leak syndrome, or the
frequency of early posttransplantation relapse.Furthermore, the two clusters showed no difference
in the frequency of various diagnoses. These observa-
tions strongly suggest that the primary hematologic
disease (all acute leukemia patients being in remission)
or residual leukemia with imminent relapse do not have
any major impact on the serum profile. Finally, the
two groups did not differ with regard to time until
neutrophil or platelet reconstitution when the patients
with early death during cytopenia were excluded from
the analysis (data not shown).
We investigated whether the risk of severe, early
transplantation-related complications differed be-
tween the two patient subsets. As severe and early com-
plications, we included acute GVHD (aGVHD),
which required treatment (grades 2-4) and early multi-
organ failure causing early mortality within 50 days af-
ter allo-SCT. Cytomegalovirus reactivation was only
seen in patients receiving treatment for GVHD, and
veno-occlusive disease was not diagnosed for any pa-
tient and suspected only for two patients with multior-
gan failure. Thus, all patients with severe/treatment-
requiring early complications were included among
the patients with aGVHD or multiorgan failure. The
12 patients in the lower patient group 3 differed
from the other groups with regard to the frequency
of serious early posttransplantation complications
(Figure 1, right part). These complications were ob-
served only for one out of the 11 patients in group 3,
whereas they were seen for 15 of the other 32 patients
(groups 1 and 2) (P 5 .0179). When the five patients
with multiorgan failure were excluded from the statis-
tical analysis, aGVHD grade 2-4 was not observed for
any of the 10 remaining patients in group 3 but for 11
of the remaining 28 patients in groups 2 and 3
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profile identifies a subset of patients with a low risk
of early, severe postransplantation complications. No
single cytokine differed significantly when comparing
patients without and with these complications. We
also performed a principal component analysis
(Figure 2) that further illustrates the variation between
the three main patient groups. All patients in group 3
(see Figure 1) are marked with open symbols and the
others with dark symbols. The analysis shows the
wide variation and the partial overlap between clusters.
Finally, linear discriminant analysis was performed
to investigate the possibility of predicting patients with
early posttransplantation complications from the pre-
transplantation cytokine levels. In this analysis, the
cytokine levels were on the original scale, the first
40 patients were included, and the cytokines IL-1a,
IL-1b, IL-4, and IL-5 were left out because of few ob-
servations above the detection level. Cross-validation
was performed because no separate validation group
was available. The model was fitted using all observa-
tions except two patients that were left out, the occur-
rence of early posttransplantation complications was
then predicted for those two left-out patients. All
possible pairs of left-out patients were tested. The pre-
diction of early posttransplantation complications
(early death or GVHD grades 2-4) based on pretrans-
plantation cytokine levels then had an overall sensitiv-
ity of 0.38 and a specificity of 0.53.
Abnormal Pretransplantation Peripheral Blood
Total Leukocyte or Neutrophil Counts, Serum
CRP, or LDH Levels Are Not Associated with
Any of the Main Patient Clusters
We compared the serum cytokine profile with pe-
ripheral blood total leukocyte (median 4.0  109/L;
range, 0.7-44.3) and neutrophil counts (median 2.4 
109/L; range, 0.4-35.5), serum C-reactive protein
(CRP) (median 3.5 mg/L; range, 1-77), and serum lac-
tate dehydrogenase (LDH) levels (median, 190 IU/L;
range, 92-1655). Total leukocyte counts were normal
(3.5-11.0  109/L) for 21 patients and decreased for
16 patients. Similarly, neutrophil counts were within
the normal range (1.4-6.5  109/L) for a majority of
23 patients and decreased levels were observed for 11
patients. The highest level of both total leukocyte
and neutrophil counts was seen for the patient with
chronic myelomonocytic leukemia. Finally, the CRP
levels were normal (\5 mg/L) for 25 patients and
increased for 13 patients, whereas the LDH levels
were within the normal range for 20 patients and
increased for 16 patients. Abnormal total leukocyte,
neutrophil, monocyte, and lymphocyte counts as well
as CRP or LDH levels did not show any significant as-
sociation with any of the four major patient clusters or
the three patient groups identified in the unsupervised
hierarchical cluster analysis (data not shown).High Pretransplantation bFGF Is Associated
with a High Early Posttransplantation Weight
Increase
The endothelial cell function can be altered by sev-
eral cytokines and is probably important in capillary
leak syndrome and fluid retention [17]. We therefore
investigated whether there was an association between
the cytokine profiles and fluid retention/weight gain in
our patients. The maximal weight increase during the
first 21 days after start of conditioning therapy did not
differ between the patient groups identified in
Figure 1. We then investigated whether there was
any correlation between weight gain and the serum
levels of individual cytokines (all 44 patients included).
bFGF did not differ between the patient groups
(Figure 1), but we observed a significant correlation
between serum bFGF levels and the maximal early
weight increase (P5 .0123, R5 .3922, Pearson corre-
lation). None of the other cytokines showed any corre-
lation with maximal weight increase (data not shown).Identification of a Low-Risk Group Based on
a Limited Number of Serum Mediator Levels
When comparing serum cytokine levels for patients
in group1 andgroup 3, significant differenceswere seen
for G-CSF (P5 .0002), IL-1RA (0.0244), and TNFR1
(0.0191), whereas when comparing serum levels for
patients in groups 2 and 3, significant differences were
observed for G-CSF (0.0054), VEGF (0.0008), CCL2
(0.0369), CD40L (0.0024), EGF (0.0028), HGF
(\0.0002), and FGF (0.0091). Based on this compari-
son, we identified those two cytokines from each
comparison (G-CSF/TNFR1 and HGF/bFGF) that
showed highly significant differences and the largest
number of patients with serum levels outside the corre-
sponding variation ranges for patients in group 3 (Table 2,
lower part). For mediators with significantly increased
serum levels in group 3 patients, the cutoff values
were defined as less than the lower value of the variation
range (G-CSF,HGF, bFGF), whereas for themediator
with significantly decreased levels among group 3 pa-
tients (TNFR1), the cutoff was defined as exceeding
the higher value of the corresponding variation range.
It can be seen from Table 2 that the serum level
for at least one of the four mediators was outside the
group 3 variation range for all patients in groups 1
and 2 (Table 2, upper part). Thus, we could identify
all patients in groups 1 and 2 based on the serum levels
of the four mediators. As can be seen from the lower
part of the table, group 3 included two exceptional
patients. Patient 25 had aGVHD and multiorgan fail-
ure (see also Figure 1). Patient 20 would be classified
together with the group 1 and 2 patients based on
the HGF level; this is because of the sensitivity of
our assay and the fact that we had to use the detection
limit as the cutoff level for HGF.
Table 2. Identification of Group 1 and Group 2 Patients (Figure 1) by the Serum Levels of G-CSF, HGF, bFGF, and TNFR1
Complication G-CSF HGF bFGF TNFR1
Group 1 (n 5 16)
1 1.6 1.4
43 MOF #1.0 5226
22 #1.0
11 #1.0 #10.0 3.2







4 MOF 0.1 2708
15 4.5 2726
33 aGVHD 2772
40 MOF 3.2 2.5
44 aGVHD #1.0 7411
Group 2 (n 5 16)
2 #10.0 2.6
8 1.6 #10.0










9 MOF #10.0 0.5 2674
39 aGVHD + MOF #10.0 2.2
10 aGVHD #1.0 #10.0 1.7
35 4.8 #10.0 2.1
Cutoff <7.6 #10.0 <5.2 >2593
Group 3 (n 5 12)
Median 29.7 381 9.8 1799




MOF indicates multiorgan failure.
Nine cytokines showed significant differences when comparing patient group 1 with group 3 and patient group 2 with group 3. We then identified those
two mediators for each of the two comparisons that showed highly significant differences and a high number of patients with levels above/below the
cutoff values, and the results for these four mediators are summarized in the table. The serum levels (pg/mL) are given only for those patients who
had levels outside the variation range of group 3 patients as defined by the cutoff points.
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Cytokine Profiles Differ for Allotransplanted
Patients
Serum samples were available from 26 of the 44 pa-
tients 3 to 6 months after the transplantation. The
other 18 patients were not included because of leuke-
mia relapse (four patients), newly diagnosed lung can-
cer (one patient), early death without relapse (nine
patients), or\3-month follow-up by the end of this
study (four patients). The overall results are summa-
rized in Table 3. It can be seen that allo-SCT altered
the cytokine profile compared with the pretransplanta-
tion levels both for immunomodulatory cytokines,
chemokines, interleukins, and growth factors.
The posttransplantation cytokine profile was
also compared with the profile in healthy controls
(Table 3). Sixteen cytokines showed altered levelsposttransplantation compared with the controls, the
most striking difference being the increased levels for
several chemokines. Thus, the differences between
pre- and posttransplantation cytokine profiles do not
represent a posttreatment normalization but rather
a new profile that differs both from the pretransplanta-
tion as well as the normal serum cytokine profiles.
Development of Chronic GVHD Shows No
Association with the Pretransplantation
Cytokine Profile
We finally investigated whether variations in
serum cytokine levels were associated with chronic
GVHD (cGVHD). A total of 32 patients could be
included in this analysis; the median observation
time was 29 months, and 13 patients did not develop
cGVHD, whereas a total of 19 patients had a sign of
Table 3. Posttransplantation Serum Cytokine Levels: A Summary of Cytokines Showing Statistically Significant Differences from
Pretransplantation Levels or Healthy Controls
Cytokine Posttransplantation Level
Alteration from
Pretransplantation Level Different from Controls
Immunomodulatory cytokines
IFN-g 6.3 (1.1-29.2) (25) [ (<.0001)* Y (.0246)
CD40L 10123 (822-25362) (26) n.s [ (<.0001)*
TNF-a 5.5 (0.50-33.4) (26) [ (.0489) n.s
Interleukins
IL-1RA 302.8 (142.9-2732) (26) Y (<.0001)* Y (.0001)*
IL-2 15.4 (8.6-35.7) (26) [ (.0001)* [ (<.0001)*
IL-10 11.1 (2.8-44.4) (25) [ (.0001)* [ (.0001)*
Chemokines
CCL2 279.3 (109.9-933.3) (26) [ (.0221) [ (.0099)
CCL3 289.1 (139.0-428.6) (22) [ (.0001)* [ (.0002)*
CCL4 74.4 (27.5-131.5) n.s [ (.0183)
CCL11 175.1 (35.6-383.5) n.s [ (.0001)*
CXCL8/IL8 19.4 (10.0-74.4) (26) n.s [ (.0001)*
CXCL10 40.8 (15.7-4902) (26) [ (.0002)* [ (<.0001)*
CXCL11 78.1 (14.2-848.0) (26) Y (.0347) [ (<.0001)*
Growth factors
TPO 990.8 (632.0-4445) [ (.0326) [ (<.0001)*
EGF 63.2 (12.7-265.3) (26) n.s [ (<.0001)*
FGFbasic 47.10 (31.55-80.86) Y (<.0001)* -
HGF 534.9 (160.6-35753) (26) [ (.0095) [ (<.0001)*
G-CSF 24.1 (7.9-185.8) [ (.0030) [ (<.0001)*
GM-CSF 0.96 (0.96-5.80) Y (<.0001)* n.s
The table shows the serum levels for 26 patients receiving allo-SCT, 3 to 6 months after transplantation. The results are presented as the patients’ levels
(median and range), the P value and alteration ([ increased, Y decreased) for patient serum posttransplantation levels compared with serum pretrans-
plantation patient levels (Wilcoxon’s test) and compared with serum levels for the healthy control group (Mann-Whitney U test), whereas significant
differences were observed. All P values <.05 are given, and values that were statistically significant also after Bonferroni correction are marked with
* All cytokine concentrations are presented as pg/mL.
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(11 patients), skin (10 patients), gastrointestinal tract
(10 patients), or liver (seven patients). When compar-
ing patients with and without cGVHD, (1) the two
groups showed no correlation with the previously
identified patient subsets (see Figure 1), (2) there was
no significant difference in pretransplantation levels
for any cytokine, and (3) for posttransplantation levels,
we only detected a significant difference in CXCL11
levels (P 5 .0130, Mann-Whitney U test).DISCUSSION
Allo-SCT includes both high-dose chemotherapy
to eradicate remaining leukemia and transplantation
of normal stem cells to replace the recipient bone mar-
row. However, stem cell grafts contain a large number
of immunocompetent cells in addition to the stem
cells, and these cells mediate antileukemic effects ei-
ther as specific graft-versus-leukemia or general
graft-versus-host reactivity. Previous studies have
shown that pretransplantation factors are important
for the posttransplantation clinical course; for exam-
ple, an increased risk of GVHD has been associated
with advanced-stage leukemia, intensive conditioning
regimens, and previous viral infections [18,19]. The
cytokine network is important in the regulation of
both normal and malignant hematopoiesis as well as
inflammatory responses to infections and tissuedamage, and in this context, we characterized the
pre- and posttransplantation serum cytokine profiles
for allotransplanted patients. We then investigated
a consecutive group of allo-SCT patients; the pre-
transplantation status for the majority of them was
acute leukemia in complete hematological remission.
Patients with a low leukemia cell burden at the time
of transplantation have a better prognosis [20], and
for this reason, all the included acute leukemia patients
received remission-inducing chemotherapy before the
transplantation.
Serum cytokine profiles of patients with AML and
MDS have been described previously [11,13]; distinct
signatures have then been detected, and these profiles
seem to have an independent prognostic impact in
AML patients receiving conventional chemotherapy
[11]. The pretransplantation levels of Ang-2 also
seem to have a prognostic impact in allotransplanted
AML patients [10], but it is not known whether this
effect is because of this single cytokine alone or due
to a systemic cytokine profile involving or affecting
Ang-2. For this reason, we investigated broad pre-
and posttransplantation cytokine profiles that included
(1) several chemokines and interleukins as well as other
immunoregulatory mediators [21,22]; (2) growth
factors involved in the regulation of normal and
leukemic hematopoiesis [23]; (3) angioregulatory cyto-
kines including Ang-2 that seem to have a prognostic
impact on leukemia patients [10,24,25]; and (4)
198 Biol Blood Marrow Transplant 18:190-199, 2012H. Reikvam et al.several chemokines important forTcellmigration and/
or possibly involved in the local recruitment of T cells
during GVHD [26]. We also included the two soluble
receptor, the IL-2 receptor and TNFR1, both these
have previously been associated withGVHD [21]. Bio-
informatical tools were used to subclassify patients ac-
cording to their cytokine profiles.
Pretransplantation cytokine levels can be affected
by several factors, including age as well as disease- and
therapy-induced alterations and eventually ongoing
complicating infections [10,18,24,27]. The cytokine
profiles for the transplantation patients and healthy
controls showed several similarities, including: (1)
generally low levels of interleukins as well as other
immunoregulatory cytokines; (2) relatively high serum
chemokine levels; and (3) relatively high levels of
several hematopoietic growth factors. Despite these
general similarities, several differences were
observed— the pretransplantation cytokine profiles
were different both for interleukins as well as other
immunoregulative cytokines, chemokines, and for the
two growth factors G-CSF and GM-CSF. Finally,
patients could be divided into three major groups based
on their serum cytokine profile (Figure 1), and patient
group 3 showed a significantly decreased frequency of
early, severe posttransplantation complications. The
patient groups/clusters did not showanymajor difference
in bone marrow function as reflected in the total leuko-
cyte or neutrophil counts, ongoing acute phase reaction
as reflected in the serumCRPlevels, or the extentof tissue
damage as reflected in the serum LDH levels.
We also performed an additional analysis of our
data by linear discriminant analysis and found that
patients with severe early posttransplantation compli-
cations could not be predicted by using this model.
These observations are consistent with the current
knowledge that the risk of severe complications/
aGVHD depends on several pre- as well as posttrans-
plantation factors. One would not expect serum cyto-
kine levels alone to identify individual patients with
high specificity/sensitivity, but our hierarchical clus-
tering shows that pretransplantation serum cytokine
profiles may be associated with prognosis and could
potentially be used to identify patient subsets with
different risk.
We identified nine cytokines that differed signifi-
cantly for low-risk group 3 patients, and based on
defined criteria, we used the serum levels for four of
these mediators to discriminate between the patient
subgroups (Table 2). We used the variation range for
group 3 patients to define cutoff points for classifica-
tion of patients, and the low-risk patient cluster (group
3) could then be identified based on the analysis of this
limited number of mediators and defined cutoff levels.
Interestingly, HGF and G-CSF were the two cyto-
kines that showed the most significant differences
when comparing patient groups 1 and 2 with group3, high levels were then associated with low risk of
posttransplantation complications. HGF has earlier
been demonstrated to have a protective role against
GVHD development in a murine model [28,29].
G-CSF also has several immunosuppressive effects as
described in detail in a recent review [30].
ThepretransplantationAng-2 levelhas aprognostic
impact in allotransplanted patients [10]. In the present
study, serum Ang-2 clustered together with G-CSF
(Figure 1). These observations suggest that the prog-
nostic impact of Ang-2 may not be caused by this cyto-
kine alone.
Our patient clustering analysis showed an associa-
tion with early death/severe GVHD but not with any
other pretransplantation (eg, diagnosis, age) or post-
transplantation characteristics (eg, capillary leak
syndrome, time to hematopoietic reconstitution, re-
lapse). However, our study is relatively small and can-
not exclude such associations.
We compared the pre- and posttransplantation
cytokine profiles in 26 patients. The profiles showed
several differences, but the posttransplantation alter-
ations do not represent a normalization of the profile
because a majority of the cytokines still differed from
the control group. The most striking difference was
then a late posttransplantation increase of several
chemokines.
Serum cytokine profiles have previously been
investigated in patients with untreated AML, MDS,
and aplastic anemia [11,13], and in all these studies,
patients were compared with healthy controls. The
cytokines investigated in these previous studies are only
partly overlapping with the cytokines examined in our
present study. Seventeen cytokines were investigated
both in our present study of pretransplantation
remission levels and the previous study of untreated
AML [11], and only 11 of these 17 showed a qualitatively
similar variation when compared with healthy controls.
This observation supports our previous conclusion that
the primary leukemia disease does not have any major
impact on patient clustering based on serum cytokine
profiles during hematologic remission. Furthermore,
only six of the 14 cytokines investigated both in our study
and the previous MDS study showed similar qualitative
variations, and as expected, our patients showed very
few similarities with aplastic anemia patients [13].
To conclude, allotransplanted patients show
abnormal pretransplantation cytokine profiles both
before and following the allo-SCT. The cytokine
profiles are also different from similar profiles previ-
ously reported in patients with untreated AML,
MDS, and aplastic anemia [11,13]. Our studies
suggest that the pretransplantation cytokine profile
may have a prognostic impact with regard to the risk
of early posttransplantation complications, but our
observations have to be confirmed in larger
prospective clinical studies.
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